
[EPISODE 24] Dr. David Berkowitz Talks Enzymes, Radiation, And The Lincoln Marathon
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
Reagent Lifecycle Management for Robust, Reproducible Assay Performance
BioAgilytix has comprehensive knowledge around critical reagent management processes to support your assay needs throughout the lifecycle of drug development – from discovery and development to post-marketing surveillance. Our approach minimizes assay performance problems caused by declining reagent activity, and can mitigate the risk of delays during preclinical and clinical studies.
What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements
with one of our scientists.
Critical reagents are those essential components of ligand-binding assays (LBAs) whose unique characteristics are crucial to assay performance and therefore require thorough characterization and documentation. Unlike other analytical technologies, these assays require specific biomolecular interactions between the critical reagents and the analyte.
Critical reagents can include binding reagents such as binding proteins, antibodies and conjugated antibodies, as well as positive and negative control. Because they are typically produced via biological processes, they are inherently prone to variability from lot to lot. Even slight production changes could significantly impact ligand binding assay performance, so a well-defined critical reagent management strategy is needed to ensure reagents are characterized, and that their structural integrity and stability are appropriately upheld through the stages of development.
This white paper discusses the considerations for the generation, production, characterization, qualification, documentation, and management of critical reagents in LBAs.
BioAgilytix seamlessly translates specialized large molecule expertise into a proven strategy for generating and maintaining high-quality critical reagents. Our expertise includes reagent qualification, commercial kit bridging, initial reagent generation, and resupply cycles. We also perform reagent generation and labeling for protein and antibodies, biotin, ruthenium, lanthanides, and fluorescein.
We offer critical reagent lifecycle management services in support of both non-regulated and regulated studies, and depending on your project or your need, we can provide either a Record of Analysis (RoA) or Certificate of Analysis (CoA). Through proactive reagent management, we ensure the quality of critical reagents is appropriate and consistent for their intended use throughout all stages of the drug development process.BioAgilytix understands and performs key risk management activities for each stage of the critical reagent lifecycle.
Sufficient lead time should be allowed to generate quality reagents, relative to the complexity and stage of the ligand binding assay. The generation of such reagents should then be properly documented for ongoing standardization.
A set of requisite physico-chemical attributes should be assigned to each particular critical reagent. These attributes will guide the generation and screening of different lots that may be qualified for use in an assay, help identify root causes of assay performance problems, and help to determine when a deteriorating reagent should be replaced.
During the span of a study, the assay may change hands and laboratories. Therefore, planning for the sufficient supply of critical reagents is needed. But inventory management also involves tracking assay performance trends and shifts to monitor critical reagent quality and identify maintenance needs over time.
It is very important to centrally consolidate scientific information on a single lot or multiple lots of critical reagents, including characterizations, source lots, qualification data, historical performance information, and more.
Download this helpful resource to discover the 8 key selection criteria you should consider when evaluating a bioanalytical CRO to ensure a successful partnership.
The inherent variability in critical reagents makes a clearly defined management system crucial – whether they are prepared in-house, outsourced, utilized individually, or as part of a commercial kit. Trust the experts in large molecule bioanalysis to accurately generate, qualify, characterize, and manage the critical reagents you need to ensure consistent, robust assay performance.
The parameters we establish around the characterization, maintenance, long-term storage, and inventorying of your critical reagents will help us successfully support the bioanalytical demands of your drug development project, from assay development and validation to timely sample analysis and data collection – as well as seamless transition of assays between laboratories as needed. Innovate faster and more effectively with BioAgilytix as your trusted bioanalytical lab partner.